Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, pharmacodynamics and pharmacokinetics of TW001 (edaravone) in patients with Alzheimer's disease
2021-003164-27Phase 2Completed
- Sponsor
- Treeway
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing TW001 (edaravone) with Placebo (2 arms). Primary endpoint: Pharmacodynamics. Started Mar 2022; status: completed.
02
Drugs
TW001
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2021-003164-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003164-27.